Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 6:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,337 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Head Neoplasms Clear all
Completed No phase listed Observational

Effects of Human Papillomavirus Diagnosis on Relationships of Patients With Head and Neck Cancer

NCT04666428
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Not listed
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Not applicable Interventional Results available

Assessing Benefits of Near Infrared Autofluorescence (NIRAF) Detection for Identifying Parathyroid Glands During Total Thyroidectomy

NCT05022667
View directory record Official record
Conditions
Thyroid Neoplasms, Thyroid Diseases, Hypoparathyroidism, Endocrine System Diseases, Endocrine Gland Neoplasms, Neoplasms by Site, Neoplasms, Head and Neck Neoplasms, Parathyroid Diseases
Interventions
PTeye
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors

NCT00313599
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Breast Cancer, Esophageal Cancer, Extragonadal Germ Cell Tumor, Gastric Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
lapatinib, paclitaxel
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 2, 2014 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Omission of Intact Parathyroid Hormone Testing During Surgery in Treating Patients With Primary Hyperparathyroidism

NCT03011736
View directory record Official record
Conditions
Parathyroid Gland Adenoma, Primary Hyperparathyroidism
Interventions
Laboratory Biomarker Analysis, Parathyroidectomy
Other · Procedure
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 8, 2026, 6:22 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Evaluation of a Cancer Lysate Vaccine and Montanide(R) ISA-51 VG With Entinostat and Nivolumab as Adjuvant Therapy Following Chemoradiation Therapy With or Without Surgery for Locally Advanced Esophageal Cancer

NCT05898828
View directory record Official record
Conditions
Neoplasms, Esophageal Neoplasms, Esophagus Neoplasm, Esophagus Cancer, Neoplasms, Esophageal, Esophageal Cancer (EsC)
Interventions
Nivolumab, Entinostat, Montanide(R) ISA-51 VG Adjuvant, H1299 Cell Lysates
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 8, 2026, 6:22 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

NCT05108870
View directory record Official record
Conditions
Human Papilloma Virus, HPV, HPV Positive Oropharyngeal Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
HB-201, HB-202, Carboplatin, Paclitaxel, Transoral Robotic Surgery
Drug · Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 24, 2026 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Preoperative Nutritional Intervention in Head and Neck Cancer

NCT03971656
View directory record Official record
Conditions
Head and Neck Cancer, Malnutrition
Interventions
Nutritional Supplement, Preoperative Dietitian Consult, Education
Dietary Supplement · Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

Cabazitaxel - PF Induction Chemotherapy

NCT01379339
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck
Interventions
Cabazitaxel 10mg/m2, Cabazitaxel 12.5mg/m2, Cabazitaxel 15mg/m2, Cabazitaxel 17.5mg/m2, Cabazitaxel 20mg/m2
Drug
Lead sponsor
Krzysztof Misiukiewicz
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Feasibility Study for Imaging of Peripheral Tumors With a High-Resolution PET Imaging System

NCT01008930
View directory record Official record
Conditions
Solid Tumors, Cancer
Interventions
HR PEM Scan
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2014 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Phase 2 Interventional Results available

FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer

NCT01747551
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Oxaliplatin, Leucovorin, Fluorouracil, Ziv-aflibercept
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Oct 8, 2026, 6:22 AM EDT
Not listed Not applicable Interventional

Wide-Area Transepithelial Sampling in Endoscopic Eradication Therapy for Barrett's Esophagus

NCT05056051
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
WATS-3D tissue sampling prior to forceps biopsies, WATS-3D tissue sampling following forceps biopsies
Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Los Angeles, California • Aurora, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Early Phase 1 Interventional

PBI-MST-01 (NCT04541108) Substudy MSD-03: Intratumoral Microdosing of Pembrolizumab Alone and With MK-0482 or MK-4830 in HNSCC or STS

NCT06413095
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Soft Tissue Sarcoma
Interventions
Pembrolizumab, MK-0482 + Pembrolizumab, MK-4830 + Pembrolizumab
Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Atlanta, Georgia • Shreveport, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated May 14, 2024 · Synced Oct 8, 2026, 6:22 AM EDT
Active, not recruiting Not applicable Interventional

Dyadic Yoga Intervention for Patient With Head and Neck Cancer Undergoing Radiotherapy and Their Family Caregivers

NCT03114501
View directory record Official record
Conditions
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Head and Neck Cancer
Interventions
Yoga, Yoga Questionnaire, Symptom Questionnaires
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Pulsed Dye Laser in Treating Patients With Post Radiation Dysphonia

NCT02198131
View directory record Official record
Conditions
Oral Complications of Radiation Therapy, Stage I Laryngeal Cancer, Stage II Laryngeal Cancer
Interventions
laser therapy, questionnaire administration
Procedure · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2023 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Phase 1 Interventional

Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.

NCT04881045
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Ovarian Cancer
Interventions
PF-07257876
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
39
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fayetteville, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

Cisplatin and Irinotecan Chemotherapy, Followed by ZD 1839 (Iressa) in Patients With Esophageal or Gastric Carcinomas

NCT00215995
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Cisplatin, Irinotecan, ZD 1839
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jan 13, 2012 · Synced Oct 8, 2026, 6:22 AM EDT
Recruiting Phase 2 Interventional

Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors

NCT07149207
View directory record Official record
Conditions
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC), Margin Assessment
Interventions
Indocyanine Green (ICG)
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Not applicable Interventional

Swallowable Sponge Cell Sampling Device and Next Generation Sequencing in Detecting Esophageal Cancer in Patients With Low or High Grade Dysplasia, Barrett Esophagus, or Gastroesophageal Reflux Disease

NCT02890979
View directory record Official record
Conditions
Barrett Esophagus, Dysplasia, Esophageal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Gastroesophageal Reflux Disease, Metaplasia
Interventions
Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Swallowable Sponge Cell Sampling Device
Other · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Phase 2 Interventional

A Study of Chemoradiotherapy for Intermediate Stage/Selected Stage IV Cancers of the Head and Neck

NCT00203905
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab, 5-Fluorouracil, Hydroxyurea-[FHX]
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 8, 2026, 6:22 AM EDT
Recruiting Phase 1 Interventional

Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors

NCT04429542
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Anal Canal, Colorectal Cancer, Squamous Cell Carcinoma of the Lung, EGFR Amplification, Epithelial Ovarian Cancer, Pancreas Cancer, Cutaneous Squamous Cell Carcinoma, Head and Neck Neoplasms, Carcinoma, Squamous Cell, Squamous Cell Carcinoma of Head and Neck
Interventions
BCA101, Pembrolizumab
Drug
Lead sponsor
Bicara Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
473 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
15
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 8, 2026, 6:22 AM EDT
Terminated Phase 2 Interventional

Oxaliplatin and Irinotecan in Recurrent or Metastatic Esophageal and Gastroesophageal (GE) Junction Carcinoma

NCT00256269
View directory record Official record
Conditions
Esophageal Cancer, Gastroesophageal Cancer
Interventions
Oxaliplatin, Irinotecan
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 26, 2018 · Synced Oct 8, 2026, 6:22 AM EDT
Active, not recruiting Not applicable Interventional

Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)

NCT06215469
View directory record Official record
Conditions
Breast Cancer, Early-stage Breast Cancer, Hair Loss, Alopecia, Chemotherapy-induced Alopecia
Interventions
Amma Portable Scalp Cooling System (PSCS), Questionnaires
Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 8, 2026, 6:22 AM EDT
Not listed Not applicable Interventional

Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection

NCT03427346
View directory record Official record
Conditions
Barrett Esophagus, Barrett Adenocarcinoma, Esophagus Neoplasm
Interventions
Endoscopic mucosal resection, Endoscopic submucosal dissection
Procedure
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Other
Eligibility
18 Years to 99 Years
Enrollment
407 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 8, 2026, 6:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers

NCT05383170
View directory record Official record
Conditions
Advanced Head and Neck Squamous Cell Carcinoma, Advanced Breast Cancer, Advanced Melanoma
Interventions
CyPep-1, Pembrolizumab 25 MG/ML [KEYTRUDA®]
Drug
Lead sponsor
Cytovation AS
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Duarte, California • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 8, 2026, 6:22 AM EDT